Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
bristol-myers squibb
11
×
merck
11
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
biotech
cancer
fda
pfizer
clinical trials
immunotherapy
roche
abbvie
amgen
glaxosmithkline
keytruda
abeona therapeutics
What
bio
roundup
drug
nash
cancer
industry
medical
pharmaceutical
policy
american
annual
based
best
clinical
companies
conference
continue
crash
data
debate
esmo
european
growing
healthcare
kind
lung
new
news
oncology
people
politicians
pressure
pricing
scalps
society
today
trump’s
u.s
advanced
advantages
Language
unset
Current search:
merck
×
" bristol-myers squibb "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front